Industry Leaders Panel Discussion: Addressing High Dose AAV Delivery

Time: 9:30 am
day: Day One


  • Have we reached the highest dose for gene therapy yet?
  • Exploring dosing strategies: “One and done or Slower and Lower?”
  • What impact would a cumulative vector genome delivery approach have on safety and efficacy?
  • Moving away from one and done: what does best practice look like for dosing strategies?
  • Which role does complement play in the context of high dose gene therapy delivery